Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Biotech·Aytu BioPharma

UK's Rosemont Pharmaceuticals to buy Aytu BioPharma for about $56 million

The Leeds-based maker of oral liquid medicines will pay $2.70 a share in cash for the Denver drugmaker behind the depression drug EXXUA and a line of ADHD treatments, a 51.7% premium to Aytu's last close before the deal.

From Aytu BioPharma announcements and SEC filings published Nov. 16, 2026
A pharmacy technician counts tablets on a counting tray while filling a prescription at Camp Leatherneck, Afghanistan, in 2013.
A pharmacy technician counts tablets on a counting tray while filling a prescription at Camp Leatherneck, Afghanistan, in 2013. File photo.Sgt. Anthony Ortiz / Wikimedia Commons (public domain)
Value
$56M
Type
Acquisition
Target
Aytu BioPharma
Buyer
Rosemont Pharmaceuticals
Sector
Pharma
Announced
Nov. 16, 2026

Aytu BioPharma has been moving its sales resources toward a new depression drug. On Nov. 16, the Denver company agreed to sell itself to a British maker of liquid medicines for about $56 million.

Aytu said it signed a definitive merger agreement under which Rosemont Pharmaceuticals Holdings will buy it for $2.70 a share in cash through a tender offer. The price is a 51.7% premium to Aytu's closing price on Nov. 13 and a 41.1% premium to its 30-day volume-weighted average price, the company said. In its quarterly results released the same day, Aytu put the total consideration at about $56 million on a fully diluted basis.

Why it matters: The deal gives Rosemont, which is based in Leeds in the United Kingdom, an established U.S. business in central nervous system drugs, which its chief executive tied to the company's U.S. growth plans. For Aytu shareholders, it arrives as the company spends to build EXXUA while revenue from its ADHD portfolio declines.

The numbers behind the sale

For the quarter ended Sept. 30, Aytu reported net revenue of $14.8 million, up 6.9% from a year earlier. Sales of EXXUA, its extended-release gepirone tablet for major depressive disorder, were $4.9 million, up 24.5% from the prior quarter, and prescriptions rose to 4,400.

Its ADHD portfolio brought in $7.7 million, down from $13.2 million a year earlier, which Aytu attributed to shifting sales resources toward EXXUA and to generic competition for Adzenys XR-ODT. Its pediatric portfolio grew to $2.2 million from $0.7 million.

Aytu posted a net loss of $3.9 million for the quarter, compared with net income of $2.0 million a year earlier, and an adjusted EBITDA loss of $2.6 million. It ended September with $25.5 million in cash. Citing the pending merger, it said it would not hold an earnings call.

The buyer

Rosemont describes itself as a global pharmaceutical company that develops, makes and supplies oral liquid medicines, with a focus for nearly 60 years on dosage forms for patients who have trouble swallowing pills. Alok Sonig, its chief executive, called the deal "an important step in Rosemont's US growth strategy."

Josh Disbrow, Aytu's chief executive, said the company saw "a strong strategic fit" between Aytu's portfolio and Rosemont's experience with specialty medicines. The announcement did not say how Rosemont will finance the purchase or who owns it.

How the deal closes

A Rosemont subsidiary will start a tender offer within 10 business days. To close, it needs a majority of Aytu's outstanding shares tendered, along with the exercise or termination of certain outstanding warrants, according to the filing. Shares not tendered will be bought at the same price in a second-step merger.

Aytu's board approved the deal unanimously. Its executives and directors, along with stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management, signed agreements to tender their shares. Viatris used the same two-step structure in its $1.65 billion deal for Pacira BioSciences, announced in October.

Aytu expects the deal to close in late December, subject to the tender offer conditions. Canaccord Genuity and Dorsey & Whitney are advising Aytu; Bourne Partners and Ropes & Gray are advising Rosemont.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Biotech

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.